Correspondence 0001193125-23-233465 from Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522) (NMRA)
Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522)
Date: Sept. 12, 2023 · CIK: 0001885522 · Accession: 0001193125-23-233465
AI Filing Summary & Sentiment
File numbers found in text: 333-274229
Show Raw Text
CORRESP 1 filename1.htm CORRESP September 12, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Daniel Crawford Re: Neumora Therapeutics, Inc. (the “Registrant”) Registration Statement on Form S-1 (File No. 333-274229) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that between September 11, 2023 and the date hereof, approximately 1,210 copies of the Preliminary Prospectus, dated September 11, 2023, were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement, as amended. We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. We hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on Thursday, September 14, 2023 or as soon thereafter as practicable. [signature page follows] Very truly yours, J.P. MORGAN SECURITIES LLC BOFA SECURITIES, INC. As representatives of the Underwriters J.P. MORGAN SECURITIES LLC By: /s/ Benjamin H. Burdett Name: Benjamin H. Burdett Title: Managing Director BOFA SECURITIES, INC. By: /s/ Michael Liloia Name: Michael Liloia Title: Director [Signature Page to Acceleration Request Letter]